CSI Market
Sign In | Register

Savient Pharmaceuticals Inc (SVNT) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access SVNT Annual Cash Flow →
This cash flow overview for Savient Pharmaceuticals Inc spans from Jun 30 2012 to Sep 30 2013, illustrating how cash generation and usage have shifted across recent reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2013)
9 Months 		(Jun 30 2013) (Mar 31 2013) (Sep 30 2012) (Jun 30 2012)
Operating Activities
Income-70.31
Depreciation & amortization0.64
Amortization of Other Assets13.47
Increase (Decrease) in Deferred Revenue13.01
Restructuring & Impairment Charges4.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-3.06
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation3.26
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.50
Change In Fair Value Of Warrant Liabilities2.79
Income taxes0.00
Losses/ -gains on Investments net1.30
Increase (Decrease) in Accounts Receivable2.48
Increase (Decrease) in Accounts Payable-1.82
Increase (Decrease) in Interest Payable, Net-0.17
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.26
Other Working Capital0.49
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-61.96
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Held-to-maturity Securities40.29
Payments to Acquire Held-to-maturity Securities-0.52
Real Estate Investments0.00
Increase (Decrease) in Restricted Cash-0.78
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net1.55
Discontinued operations0.00
Net Cash Flow from Investing Activities40.54
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.14
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Issuance Of Common Stock For Cash On Registered Direct Offering Net-
Stock Repurchased And Retired During Period Value-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.14
Effect of exchange rate on cash flow-0.61
Discontinued operations0.00
Free Cash Flow-61.96
Total Cash Flow-21.89
4 historic quarters locked

Sign in to unlock the full Savient Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About SVNT Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.